[Changes of plasma fibrinolysis system and the effect of captopril in high altitude pulmonary edema].
To investigate the changes of plasma fibrinolysis system and the effect of captopril in patients with high altitude pulmonary edema. The plasma levels of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) were measured before and after treatment in the captopril-group (group A, 35 cases) and the routine-group (group B, 37 cases) of patients with HAPE, while 20 healthy volunteers served as the control (group C). The plasma level of tPA was (0.40 +/- 0.14) x 10(3) IU/L in group A vs (0.39 +/- 0.19) x 10(3) IU/L in group B before treatment, and (0.58 +/- 0.13) x 10(3) IU/L vs (0.49 +/- 0.16) x 10(3) IU/L after treatment, and (0.59 +/- 0.17) x 10(3) IU/L in group C. The differences were significant both before and after treatment between group A and group B (P < 0.01, P < 0.05). While PAI-1 was (6.6 +/- 1.8) x 10(3) AU/L in group A vs (6.6 +/- 1.6) x 10(3) AU/L in group B before treatment, and (4.9 +/- 1.5) x 10(3) AU/L vs (5.8 +/- 1.7) x 10(3) AU/L after treatment, and (4.9 +/- 1.3) x 10(3) AU/L in group C. The differences were significant both before and after treatment between group A and group B (P < 0.01, P < 0.05). Patients with HAPE may present a disturbance of the fibrinolysis system, which could be reversed by captopril.